ACG to invest $200 million in U.S. hard-shell capsule manufacturing
Dedicated facilities for gelatin and HPMC; 200+ jobs; operations targeted for early 2027; expands ACG’s 25-year U.S. presence
Dedicated facilities for gelatin and HPMC; 200+ jobs; operations targeted for early 2027; expands ACG’s 25-year U.S. presence
ACG, the world’s largest integrated supplier of pharmaceutical capsules and allied solutions, welcomes the European Commission’s recent announcement allowing the continued use of titanium dioxide in medicinal products.
ACG has been deeply involved with this matter since the very inception of the concern, working on two fronts.
On one side, the company has invested in the development of TiO2-free alternatives to support customer needs.